Trial Profile

A Multicenter, Randomized,Double blind study of Gildeuretinol (ALK-001) in patients with Stargardt disease.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gildeuretinol (Primary)
Indications Stargardt disease
Focus Therapeutic Use
Acronyms TEASE-1
Sponsors Alkeus Pharmaceuticals

Most Recent Events

11 Feb 2025 According to the Alkeus Pharmaceuticals Media Release, safety and efficacy results from TEASE program will be presented at the 48th Annual Meeting of the Macula Society being held February 12-15 in Charlotte Harbor, Fla.
05 Dec 2024 According to the Alkeus Pharmaceuticals Media Release, company announced that the results from this study will be orally presented at the 12th International FLORetina ICOOR Congress being held December 5-8 in Florence, Italy.
01 May 2024 Results published in the Alkeus Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com